Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EDP 305

Next Previous
X
Search
Drug Profile

EDP 305

Alternative Names: EDP-305

Latest Information Update: 29 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Antifibrotics; Hepatoprotectants; Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary biliary cirrhosis

Most Recent Events

  • 30 Nov 2021 Enanta Pharmaceuticals terminates the phase II ARGON-2 trial for Non-alcoholic-steatohepatitis in USA, Argentina, Canada, Germany, Puerto Rico, and United Kingdom based on a strategic decision to prioritize combination treatment approaches (NCT04378010)
  • 15 Oct 2021 Discontinued - Phase-I for Non-alcoholic fatty liver disease in USA (PO)
  • 15 Oct 2021 Discontinued - Phase-I for Non-alcoholic steatohepatitis (In volunteers) in Slovakia, Czech Republic (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top